

# GUYANA

Number of new cases

**1 225**

Number of deaths

**612**

Number of prevalent cases (5-year)

**2 775**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	400 004	394 035	794 039
<b>Incidence*</b>			
Number of new cancer cases	537	688	1 225
Age-standardized incidence rate	130.1	157.7	142.5
Risk of developing cancer before the age of 75 years (cum. risk %)	13.6	16.3	14.9
Top 3 leading cancers (ranked by cases)**	Prostate Colorectum NHL	Breast Cervix uteri Colorectum	Prostate Breast Cervix uteri
<b>Mortality*</b>			
Number of cancer deaths	271	341	612
Age-standardized mortality rate	64.7	76.6	70.2
Risk of dying from cancer before the age of 75 years (cum. risk %)	6.3	8.5	7.4
Top 3 leading cancers (ranked by deaths)**	Prostate Colorectum Lung	Breast Cervix uteri Colorectum	Prostate Breast Cervix uteri
<b>Prevalence*</b>			
5-year prevalent cases	1 084	1 691	2 775



## Top 5 most frequent cancers\*\*


**Males**



Rank	Cancer site	Number of cases	Percent
1st	Prostate	259	48.2%
2nd	Colorectum	43	8.0%
3rd	NHL	30	5.6%
4th	Lung	26	4.8%
5th	Stomach	21	3.9%
-	Others	158	29.4%

Number of new cases in 2022, males, all ages


**Females**



Rank	Cancer site	Number of cases	Percent
1st	Breast	229	33.3%
2nd	Cervix uteri	129	18.8%
3rd	Colorectum	36	5.2%
4th	Corpus uteri	32	4.7%
5th	Ovary	19	2.8%
-	Others	243	35.3%

Number of new cases in 2022, females, all ages

**Both sexes**



Rank	Cancer site	Number of cases	Percent
1st	Prostate	259	21.1%
2nd	Breast	229	18.7%
3rd	Cervix uteri	129	10.5%
4th	Colorectum	79	6.4%
5th	NHL	47	3.8%
-	Others	482	39.3%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Prostate	259	1	21.1	6.6	89	1	14.5	1.7	519	18.7
Breast	229	2	18.7	5.6	67	2	10.9	1.6	648	23.4
Cervix uteri	129	3	10.5	3.3	65	3	10.6	1.8	366	13.2
Colorectum	79	4	6.4	0.91	46	4	7.5	0.45	197	7.1
NHL	47	5	3.8	0.64	21	8	3.4	0.29	140	5.0
Stomach	38	6	3.1	0.49	27	7	4.4	0.34	60	2.2
Lung	37	7	3.0	0.50	34	5	5.6	0.42	49	1.8
Corpus uteri	32	8	2.6	0.77	11	12	1.8	0.26	100	3.6
Leukaemia	31	9	2.5	0.28	18	9	2.9	0.18	94	3.4
Liver	30	10	2.4	0.43	28	6	4.6	0.41	42	1.5
Ovary	19	11	1.6	0.51	15	11	2.5	0.42	50	1.8
Pancreas	18	12	1.5	0.22	16	10	2.6	0.21	17	0.61
Kidney	16	13	1.3	0.30	8	13	1.3	0.15	44	1.6
Larynx	11	14	0.90	0.18	6	15	0.98	0.09	32	1.2
Lip, oral cavity	10	15	0.82	0.14	8	13	1.3	0.11	25	0.90
Bladder	10	15	0.82	0.08	3	17	0.49	0.02	26	0.94
Oesophagus	7	17	0.57	0.08	5	16	0.82	0.05	12	0.43
Thyroid	7	17	0.57	0.18	1	20	0.16	0.03	18	0.65
Gallbladder	4	19	0.33	0.07	1	20	0.16	0.03	7	0.25
Penis	4	19	0.33	0.14	1	20	0.16	0.03	12	0.43
Vulva	3	21	0.25	0.04	0	23	0.00	0.00	8	0.29
Multiple myeloma	3	21	0.25	0.06	3	17	0.49	0.06	8	0.29
Oropharynx	2	23	0.16	0.04	0	23	0.00	0.00	5	0.18
Hypopharynx	2	23	0.16	0.03	0	23	0.00	0.00	4	0.14
Brain CNS	2	23	0.16	0.02	2	19	0.33	0.02	8	0.29
Salivary glands	1	26	0.08	0.00	0	23	0.00	0.00	2	0.07
Nasopharynx	1	26	0.08	0.03	0	23	0.00	0.00	2	0.07
Testis	1	26	0.08	0.05	0	23	0.00	0.00	3	0.11
Melanoma	0	29	0.00	0.00	0	23	0.00	0.00	0	0.00
Mesothelioma	0	29	0.00	0.00	0	23	0.00	0.00	0	0.00
Kaposi sarcoma	0	29	0.00	0.00	0	23	0.00	0.00	0	0.00
Vagina	0	29	0.00	0.00	0	23	0.00	0.00	0	0.00
<b>All cancers</b>	<b>1 225</b>	-	-	<b>14.9</b>	<b>612</b>	-	-	<b>7.4</b>	<b>2 775</b>	-
<b>All cancers excl. NMSC</b>	<b>1 223</b>	-	-	<b>14.8</b>	<b>612</b>	-	-	<b>7.4</b>	<b>2 769</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** No data  
**Method:** Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

### Mortality

**Country-specific data source:** National (WHO)  
**Method:** National rates projected to 2022

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

